|Awarded On||November 19, 2014|
|Title||Preclinical Development of a Therapeutic Enzyme for Immune Checkpoint Inhibition in Cancer|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||George Georgiou|
|Cancer Sites||Lung and Bronchus, Melanoma|
Cancer cells only survive if they can keep the immune system from recognizing and eliminating them. One way that some forms of cancers do this is through the product of the immunosuppressive molecule Kyn. Kyn is produced when the amino acid Tryptophan is oxidized by one of three possible enzymes (i.e. IDO1, IDO2, TDO). Kyn is then transported outside the cell where it initiates ‘tumor tolerance’ by impeding the function of crucial cancer-fighting T cells. Therapeutics developed to specifically reverse this kind of tumor-induced immune suppression (i.e. “immune checkpoint inhibitors”) are increasingly popular, as evident by the number of recently adopted clinical trials.
In the case of Kyn, ...